No biomarker
|
MDS
|
No biomarker
|
MDS
|
decitabine/cedazuridine Sensitive: A1 - Approval
|
decitabine / cedazuridine Sensitive: A1 - Approval
|
No biomarker
|
MDS
|
No biomarker
|
MDS
|
luspatercept-aamt Sensitive: A1 - Approval
|
luspatercept-aamt Sensitive: A1 - Approval
|
Chr del(5q)
|
MDS
|
Chr del(5q)
|
MDS
|
lenalidomide Sensitive: A1 - Approval
|
lenalidomide Sensitive: A1 - Approval
|
No biomarker
|
MDS
|
No biomarker
|
MDS
|
azacitidine Sensitive: A1 - Approval
|
azacitidine Sensitive: A1 - Approval
|
No biomarker
|
MDS
|
No biomarker
|
MDS
|
decitabine Sensitive: A1 - Approval
|
decitabine Sensitive: A1 - Approval
|
PDGFRA rearrangement
|
MDS
|
PDGFRA rearrangement
|
MDS
|
imatinib Sensitive: A1 - Approval
|
imatinib Sensitive: A1 - Approval
|
CALR mutation
|
MDS
|
CALR mutation
|
MDS
|
luspatercept-aamt Sensitive: A2 - Guideline
|
luspatercept-aamt Sensitive: A2 - Guideline
|
CALR mutation
|
MDS
|
CALR mutation
|
MDS
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
MPL W515L
|
MDS
|
MPL W515L
|
MDS
|
luspatercept-aamt Sensitive: A2 - Guideline
|
luspatercept-aamt Sensitive: A2 - Guideline
|
MPL W515L
|
MDS
|
MPL W515L
|
MDS
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
JAK2 V617F
|
MDS
|
JAK2 V617F
|
MDS
|
luspatercept-aamt Sensitive: A2 - Guideline
|
luspatercept-aamt Sensitive: A2 - Guideline
|
SF3B1 mutation
|
MDS
|
SF3B1 mutation
|
MDS
|
luspatercept-aamt Sensitive: A2 - Guideline
|
luspatercept-aamt Sensitive: A2 - Guideline
|
JAK2 V617F
|
MDS
|
JAK2 V617F
|
MDS
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
RUNX1 mutation
|
MDS
|
RUNX1 mutation
|
MDS
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
SETBP1 mutation
|
MDS
|
SETBP1 mutation
|
MDS
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
CBL mutation
|
MDS
|
CBL mutation
|
MDS
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
NRAS mutation
|
MDS
|
NRAS mutation
|
MDS
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
ASXL1 mutation
|
MDS
|
ASXL1 mutation
|
MDS
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
SRSF2 mutation
|
MDS
|
SRSF2 mutation
|
MDS
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
TET2 mutation
|
MDS
|
TET2 mutation
|
MDS
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
ETNK1 mutation
|
MDS
|
ETNK1 mutation
|
MDS
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
STAT3 mutation
|
MDS
|
STAT3 mutation
|
MDS
|
eltrombopag + cyclosporin A microemulsion Sensitive: A2 - Guideline
|
eltrombopag + cyclosporin A microemulsion Sensitive: A2 - Guideline
|
No biomarker
|
MDS
|
No biomarker
|
MDS
|
eltrombopag + cyclosporin A microemulsion Sensitive: A2 - Guideline
|
eltrombopag + cyclosporin A microemulsion Sensitive: A2 - Guideline
|
TP53 mutation
|
MDS
|
TP53 mutation
|
MDS
|
APR-246 Sensitive: B - Late Trials
|
APR-246 Sensitive: B - Late Trials
|
No biomarker
|
MDS
|
No biomarker
|
MDS
|
GS-4721 Sensitive: B - Late Trials
|
GS-4721 Sensitive: B - Late Trials
|
DNMT3A mutation + SF3B1 mutation
|
MDS
|
DNMT3A mutation + SF3B1 mutation
|
MDS
|
lenalidomide Resistant: B - Late Trials
|
lenalidomide Resistant: B - Late Trials
|
No biomarker
|
MDS
|
No biomarker
|
MDS
|
MLN4924 Sensitive: B - Late Trials
|
MLN4924 Sensitive: B - Late Trials
|
No biomarker
|
MDS
|
No biomarker
|
MDS
|
lenalidomide Sensitive: B - Late Trials
|
lenalidomide Sensitive: B - Late Trials
|
Chr del(5)(q31)
|
MDS
|
Chr del(5)(q31)
|
MDS
|
lenalidomide Sensitive: B - Late Trials
|
lenalidomide Sensitive: B - Late Trials
|
No biomarker
|
MDS
|
No biomarker
|
MDS
|
Hypomethylating agent + MBG453 Sensitive: B - Late Trials
|
Hypomethylating agent + MBG453 Sensitive: B - Late Trials
|
No biomarker
|
MDS
|
No biomarker
|
MDS
|
venetoclax Sensitive: B - Late Trials
|
venetoclax Sensitive: B - Late Trials
|
IDH1 mutation
|
MDS
|
IDH1 mutation
|
MDS
|
ivosidenib Sensitive: C1 - Off-label
|
ivosidenib Sensitive: C1 - Off-label
|
TP53 mutation
|
MDS
|
TP53 mutation
|
MDS
|
CB-839 Sensitive: C2 – Inclusion Criteria
|
CB-839 Sensitive: C2 – Inclusion Criteria
|
FLT3 mutation
|
MDS
|
FLT3 mutation
|
MDS
|
ARO-002 Sensitive: C2 – Inclusion Criteria
|
ARO-002 Sensitive: C2 – Inclusion Criteria
|
TP53 mutation
|
MDS
|
TP53 mutation
|
MDS
|
decitabine Sensitive: C2 – Inclusion Criteria
|
decitabine Sensitive: C2 – Inclusion Criteria
|
TET2 mutation
|
MDS
|
TET2 mutation
|
MDS
|
azacitidine Sensitive: C2 – Inclusion Criteria
|
azacitidine Sensitive: C2 – Inclusion Criteria
|
TP53 mutation
|
MDS
|
TP53 mutation
|
MDS
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
RUNX1 mutation
|
MDS
|
RUNX1 mutation
|
MDS
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
ASXL1 mutation
|
MDS
|
ASXL1 mutation
|
MDS
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
IDH2 mutation
|
MDS
|
IDH2 mutation
|
MDS
|
enasidenib Sensitive: C2 – Inclusion Criteria
|
enasidenib Sensitive: C2 – Inclusion Criteria
|
FLT3 mutation
|
MDS
|
FLT3 mutation
|
MDS
|
quizartinib Sensitive: C2 – Inclusion Criteria
|
quizartinib Sensitive: C2 – Inclusion Criteria
|
CBL mutation
|
MDS
|
CBL mutation
|
MDS
|
quizartinib Sensitive: C2 – Inclusion Criteria
|
quizartinib Sensitive: C2 – Inclusion Criteria
|
SF3B1 mutation
|
MDS
|
SF3B1 mutation
|
MDS
|
CA-4948 Sensitive: C2 – Inclusion Criteria
|
CA-4948 Sensitive: C2 – Inclusion Criteria
|
U2AF1 mutation
|
MDS
|
U2AF1 mutation
|
MDS
|
CA-4948 Sensitive: C2 – Inclusion Criteria
|
CA-4948 Sensitive: C2 – Inclusion Criteria
|
MECOM mutation + KDM6B mutation
|
MDS
|
MECOM mutation + KDM6B mutation
|
MDS
|
lenalidomide Sensitive: C3 – Early Trials
|
lenalidomide Sensitive: C3 – Early Trials
|
MECOM mutation + KDM6A mutation
|
MDS
|
MECOM mutation + KDM6A mutation
|
MDS
|
lenalidomide Sensitive: C3 – Early Trials
|
lenalidomide Sensitive: C3 – Early Trials
|
RUNX1 mutation
|
MDS
|
RUNX1 mutation
|
MDS
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
DNMT3A mutation
|
MDS
|
DNMT3A mutation
|
MDS
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
ASXL1 mutation
|
MDS
|
ASXL1 mutation
|
MDS
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
TET2 mutation
|
MDS
|
TET2 mutation
|
MDS
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
BNIP3L elevation
|
MDS
|
BNIP3L elevation
|
MDS
|
azacitidine Sensitive: C3 – Early Trials
|
azacitidine Sensitive: C3 – Early Trials
|
LDHA elevation
|
MDS
|
LDHA elevation
|
MDS
|
azacitidine Sensitive: C3 – Early Trials
|
azacitidine Sensitive: C3 – Early Trials
|
HIF1A overexpression
|
MDS
|
HIF1A overexpression
|
MDS
|
azacitidine Sensitive: C3 – Early Trials
|
azacitidine Sensitive: C3 – Early Trials
|
TP53 mutation
|
MDS
|
TP53 mutation
|
MDS
|
cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials
|
cytarabine / daunorubicin liposomal formulation Sensitive: C3 – Early Trials
|
PIK3CD mutation
|
MDS
|
PIK3CD mutation
|
MDS
|
lenalidomide Resistant: C3 – Early Trials
|
lenalidomide Resistant: C3 – Early Trials
|
PLCG2 mutation
|
MDS
|
PLCG2 mutation
|
MDS
|
lenalidomide Resistant: C3 – Early Trials
|
lenalidomide Resistant: C3 – Early Trials
|
AKT3 mutation
|
MDS
|
AKT3 mutation
|
MDS
|
lenalidomide Resistant: C3 – Early Trials
|
lenalidomide Resistant: C3 – Early Trials
|
TMB-H
|
MDS
|
TMB-H
|
MDS
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
SF3B1 K700E
|
MDS
|
SF3B1 K700E
|
MDS
|
Hypomethylating agent Sensitive: C3 – Early Trials
|
Hypomethylating agent Sensitive: C3 – Early Trials
|
SF3B1 mutation + Chr del(5q)
|
MDS
|
SF3B1 mutation + Chr del(5q)
|
MDS
|
lenalidomide Resistant: C3 – Early Trials
|
lenalidomide Resistant: C3 – Early Trials
|
Chr del(20q) + ASXL1 mutation
|
MDS
|
Chr del(20q) + ASXL1 mutation
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
Chr del(20q) + ASXL1 deletion
|
MDS
|
Chr del(20q) + ASXL1 deletion
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
DNMT3A mutation
|
MDS
|
DNMT3A mutation
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
DNMT3A mutation
|
MDS
|
DNMT3A mutation
|
MDS
|
decitabine Resistant: C3 – Early Trials
|
decitabine Resistant: C3 – Early Trials
|
TP53 mutation
|
MDS
|
TP53 mutation
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
U2AF1 mutation
|
MDS
|
U2AF1 mutation
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
U2AF1 mutation
|
MDS
|
U2AF1 mutation
|
MDS
|
decitabine Resistant: C3 – Early Trials
|
decitabine Resistant: C3 – Early Trials
|
NPM1 mutation
|
MDS
|
NPM1 mutation
|
MDS
|
decitabine Sensitive: C3 – Early Trials
|
decitabine Sensitive: C3 – Early Trials
|
RRM1 underexpression
|
MDS
|
RRM1 underexpression
|
MDS
|
azacitidine Sensitive: C3 – Early Trials
|
azacitidine Sensitive: C3 – Early Trials
|
Chr del(5q) + TP53 expression
|
MDS
|
Chr del(5q) + TP53 expression
|
MDS
|
lenalidomide Resistant: C3 – Early Trials
|
lenalidomide Resistant: C3 – Early Trials
|
Chr del(5)(q31.1)
|
MDS
|
Chr del(5)(q31.1)
|
MDS
|
lenalidomide Sensitive: C3 – Early Trials
|
lenalidomide Sensitive: C3 – Early Trials
|
SF3B1 mutation
|
MDS
|
SF3B1 mutation
|
MDS
|
lenalidomide Resistant: C3 – Early Trials
|
lenalidomide Resistant: C3 – Early Trials
|
EZH2 mutation
|
MDS
|
EZH2 mutation
|
MDS
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
SLFN11 expression
|
MDS
|
SLFN11 expression
|
MDS
|
BGB324 Sensitive: C3 – Early Trials
|
BGB324 Sensitive: C3 – Early Trials
|
ANG elevation
|
MDS
|
ANG elevation
|
MDS
|
BGB324 Sensitive: C3 – Early Trials
|
BGB324 Sensitive: C3 – Early Trials
|
AXL elevation
|
MDS
|
AXL elevation
|
MDS
|
BGB324 Sensitive: C3 – Early Trials
|
BGB324 Sensitive: C3 – Early Trials
|
JDP2 overexpression
|
MDS
|
JDP2 overexpression
|
MDS
|
azacitidine Sensitive: C3 – Early Trials
|
azacitidine Sensitive: C3 – Early Trials
|
SPI1 overexpression
|
MDS
|
SPI1 overexpression
|
MDS
|
azacitidine Sensitive: C3 – Early Trials
|
azacitidine Sensitive: C3 – Early Trials
|
Chr del(17p)
|
MDS
|
Chr del(17p)
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
NPM1 mutation
|
MDS
|
NPM1 mutation
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
SETBP1 mutation
|
MDS
|
SETBP1 mutation
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
RUNX1 mutation
|
MDS
|
RUNX1 mutation
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
IDH1 mutation
|
MDS
|
IDH1 mutation
|
MDS
|
venetoclax + ivosidenib Sensitive: C3 – Early Trials
|
venetoclax + ivosidenib Sensitive: C3 – Early Trials
|
TP53 mutation
|
MDS
|
TP53 mutation
|
MDS
|
MBG453 Sensitive: C3 – Early Trials
|
MBG453 Sensitive: C3 – Early Trials
|
ASXL1 mutation
|
MDS
|
ASXL1 mutation
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
ASXL1 deletion
|
MDS
|
ASXL1 deletion
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
TP53 mutation
|
MDS
|
TP53 mutation
|
MDS
|
azacitidine + MBG453 Sensitive: C3 – Early Trials
|
azacitidine + MBG453 Sensitive: C3 – Early Trials
|
TP53 mutation
|
MDS
|
TP53 mutation
|
MDS
|
decitabine + MBG453 Sensitive: C3 – Early Trials
|
decitabine + MBG453 Sensitive: C3 – Early Trials
|
ASXL1 mutation
|
MDS
|
ASXL1 mutation
|
MDS
|
venetoclax + azacitidine Sensitive: C3 – Early Trials
|
venetoclax + azacitidine Sensitive: C3 – Early Trials
|
TP53 mutation
|
MDS
|
TP53 mutation
|
MDS
|
ALX148 Sensitive: C3 – Early Trials
|
ALX148 Sensitive: C3 – Early Trials
|
FGFR1 rearrangement
|
MDS
|
FGFR1 rearrangement
|
MDS
|
pemigatinib Sensitive: C3 – Early Trials
|
pemigatinib Sensitive: C3 – Early Trials
|
TP53 mutation
|
MDS
|
TP53 mutation
|
MDS
|
venetoclax + tagraxofusp Sensitive: C3 – Early Trials
|
venetoclax + tagraxofusp Sensitive: C3 – Early Trials
|